QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
NASDAQ:SNGX

Soligenix (SNGX) Stock Price, News & Analysis

$0.41
-0.03 (-5.85%)
(As of 04:24 PM ET)
Today's Range
$0.40
$0.43
50-Day Range
$0.39
$0.82
52-Week Range
$0.37
$4.20
Volume
622,700 shs
Average Volume
3.06 million shs
Market Capitalization
$4.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Soligenix MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
641.8% Upside
$3.00 Price Target
Short Interest
Healthy
1.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Soligenix in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.81 to ($0.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.47 out of 5 stars

SNGX stock logo

About Soligenix Stock (NASDAQ:SNGX)

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

SNGX Stock Price History

SNGX Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Why Is Penny Stock Soligenix Trading Higher On Monday?
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Soligenix's MarVax Gets Orphan Drug Designation
Why Are Stocks Up Today?
Why Is Soligenix (SNGX) Stock Up 58% Today?
Solinex Down On Orphan Drug Designation
Recap: Soligenix Q4 Earnings
Soligenix Inc.
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2024
Today
4/22/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNGX
Employees
13
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+625.9%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-6,140,000.00
Net Margins
-731.94%
Pretax Margin
-942.67%

Debt

Sales & Book Value

Annual Sales
$840,000.00
Book Value
$0.24 per share

Miscellaneous

Free Float
10,381,000
Market Cap
$4.35 million
Optionable
Not Optionable
Beta
1.81

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

SNGX Stock Analysis - Frequently Asked Questions

What is Soligenix's stock price target for 2024?

0 brokerages have issued 12-month price objectives for Soligenix's shares. Their SNGX share price targets range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 641.8% from the stock's current price.
View analysts price targets for SNGX
or view top-rated stocks among Wall Street analysts.

How have SNGX shares performed in 2024?

Soligenix's stock was trading at $0.7572 at the beginning of 2024. Since then, SNGX stock has decreased by 46.6% and is now trading at $0.4044.
View the best growth stocks for 2024 here
.

Are investors shorting Soligenix?

Soligenix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 115,800 shares, an increase of 71.0% from the March 15th total of 67,700 shares. Based on an average daily trading volume, of 272,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.1% of the company's shares are short sold.
View Soligenix's Short Interest
.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SNGX earnings forecast
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) released its earnings results on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 731.94% and a negative trailing twelve-month return on equity of 251.07%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNGX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners